Viatris Inc.

10.09+0.3600+3.70%Vol 38.11M1Y Perf -31.72%
Aug 8th, 2022 16:00 DELAYED
BID10.00 ASK10.13
Open10.18 Previous Close9.73
Pre-Market- After-Market10.46
 - -  0.37 3.68%
Target Price
11.83 
Analyst Rating
Hold 3.29
Potential %
17.24 
Finscreener Ranking
★★     44.76
Insiders Trans % 3/6/12 mo.
-/100/100 
Value Ranking
★+     43.35
Insiders Value % 3/6/12 mo.
-/100/100 
Growth Ranking
★+     41.50
Insiders Shares Cnt. % 3/6/12 mo.
-/100/100 
Income Ranking
     32.34
Price Range Ratio 52W %
10.48 
Earnings Rating
Market Cap12.23B 
Earnings Date
8th Aug 2022
Alpha-0.02 Standard Deviation0.11
Beta0.66 

Today's Price Range

10.0210.62

52W Range

9.4515.60

5 Year PE Ratio Range

-10.80770.30

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
3.91%
1 Month
-2.51%
3 Months
-3.72%
6 Months
-34.48%
1 Year
-31.72%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
VTRS10.090.36003.70
AAPL164.87-0.4800-0.29
GOOG118.14-0.0800-0.07
MSFT280.32-2.5900-0.92
XOM88.950.50000.57
WFC43.19-0.5700-1.30
JNJ170.20-0.9100-0.53
FB196.640.99000.51
GE75.180.82001.10
JPM114.35-1.4100-1.22
 
ProfitabilityValueIndustryS&P 500US Markets
34.50
5.20
26.80
0.20
2.98
RevenueValueIndustryS&P 500US Markets
13.07B
10.78
15.57
7.31
Earnings HistoryEstimateReportedSurprise %
Q01 20220.810.9314.81
Q04 20210.820.80-2.44
Q03 20210.860.9915.12
Q02 20210.880.9811.36
Q01 20210.790.9216.46
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report0.81
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume38.11M
Shares Outstanding1.21M
Shares Float1.08B
Trades Count124.88K
Dollar Volume391.42M
Avg. Volume10.93M
Avg. Weekly Volume10.53M
Avg. Monthly Volume11.27M
Avg. Quarterly Volume10.99M

Viatris Inc. (NASDAQ: VTRS) stock closed at 10.09 per share at the end of the most recent trading day (a 3.7% change compared to the prior day closing price) with a volume of 38.11M shares and market capitalization of 12.23B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 40000 people. Viatris Inc. CEO is Michael Goettler.

The one-year performance of Viatris Inc. stock is -31.72%, while year-to-date (YTD) performance is -25.42%. VTRS stock has a five-year performance of %. Its 52-week range is between 9.445 and 15.6, which gives VTRS stock a 52-week price range ratio of 10.48%

Viatris Inc. currently has a PE ratio of 70.40, a price-to-book (PB) ratio of 0.58, a price-to-sale (PS) ratio of 0.91, a price to cashflow ratio of 3.60, a PEG ratio of 2.32, a ROA of 0.31%, a ROC of 1.21% and a ROE of 0.82%. The company’s profit margin is 2.98%, its EBITDA margin is 26.80%, and its revenue ttm is $13.07 Billion , which makes it $10.78 revenue per share.

Of the last four earnings reports from Viatris Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.81 for the next earnings report. Viatris Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Viatris Inc. is Hold (3.29), with a target price of $11.83, which is +17.24% compared to the current price. The earnings rating for Viatris Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Viatris Inc. has a dividend yield of 4.88% with a dividend per share of $0.48 and a payout ratio of -%.

Viatris Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 40.63, ATR14 : 0.36, CCI20 : -96.28, Chaikin Money Flow : 0.05, MACD : -0.24, Money Flow Index : 49.76, ROC : -2.41, RSI : 25.56, STOCH (14,3) : 36.31, STOCH RSI : 1.00, UO : 47.16, Williams %R : -63.69), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Viatris Inc. in the last 12-months were: Dillon JoEllen Lyons (Option Excercise at a value of $0), Harry A. Korman (Option Excercise at a value of $0), Ian C. Read (Option Excercise at a value of $0), James M. Kilts (Option Excercise at a value of $0), Mark W. Parrish (Option Excercise at a value of $0), Melina E. Higgins (Option Excercise at a value of $0), Menassie Taddese (Option Excercise at a value of $0), Michael Goettler (Buy at a value of $496 773), Michael Goettler (Option Excercise at a value of $0), Neil F. Dimick (Option Excercise at a value of $0), Pauline F.M. van der Meer Mohr (Option Excercise at a value of $0), Richard A. Mark (Option Excercise at a value of $0), Wyllie Don Cornwell (Buy at a value of $26 721), Wyllie Don Cornwell (Option Excercise at a value of $0), Xiangyang Ni (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (14.29 %)
1 (14.29 %)
1 (14.29 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (57.14 %)
4 (57.14 %)
6 (85.71 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
2 (28.57 %)
2 (28.57 %)
0 (0.00 %)
Summary RatingHold
3.29
Hold
3.29
Hold
2.71

Viatris Inc.

The new entity will largely be led by Pfizer executives and will be registered in Delaware. The new entity is anticipated to leverage the stand-alone Mylan infrastructure consisting of roughly 55 manufacturing and research and development facilities and that were largely acquired, including Matrix Laboratories and the generics business of Germany-based Merck KGaA. The combined portfolio will consist of the mature Upjohn drugs with notably better economics and Mylan's portfolio of more than 7,500 generic, specialty, and over-the-counter active ingredients and medicines, including EpiPen (treatment for anaphylaxis acquired through the Merck KGaA transaction). Unlike its generic peers, the company has made the most progress on the biosimilar front.

CEO: Michael Goettler

Telephone: +1 724 514-1800

Address: 1000 Mylan Boulevard, Canonsburg 15317, PA, US

Number of employees: 40 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

52%48%

Bearish Bullish

63%37%


News

Stocktwits